Dr. William Davis McLaughlin, MD

Dr. McLaughlin practices at Digestive Health Specialists in Dothan, Alabama.

Dr. McLaughlin's NPI, 1104870971, was assigned on May 19, 2006. Dr. McLaughlin holds Alabama license 12752.

Dr. McLaughlin's primary practice is Digestive Health Specialists, at 480 Honeysuckle Road, Dothan, AL 36305. The practice phone is (334) 836-1212.

Dr. McLaughlin's primary practice is Digestive Health Specialists in Dothan, Alabama. The medical group on file is Digestive Health Specialists. Dmand AI also links Dr. McLaughlin to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. McLaughlin's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McLaughlin practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. McLaughlin's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. McLaughlin's licenses on file in 2 states: Alabama and Georgia.

Dmand AI lists acid reflux, acute gastroduodenitis, chronic indigestion, chronic inflammatory bowel disease (IBD), cirrhosis of the liver, colonoscopy, fatty liver and gastroduodenitis among the conditions Dr. McLaughlin treats.

CMS data shows 12,758 Medicare services from Dr. McLaughlin across 29 procedure codes in 2024, for 757 Medicare patients. Medicare paid $265,731 for them.

CMS counts 757 Medicare patients who saw Dr. McLaughlin in 2024. The largest group is 65 to 74, with 318 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. McLaughlin's median patient age at 67, with 55% women.

In 2024, Dr. McLaughlin wrote 4,439 Medicare Part D claims for 1,087 patients. 83% of them were for generic drugs. CMS names the drug for 4,190 of them, across 40 drugs with 11 or more claims each, at $1,496,608 in total drug cost. In 2023, CMS named 4,263 claims across 47 drugs.

Dmand AI links Dr. McLaughlin to 2 clinical trials, 2 of them phase 3 studies. Conditions studied include Non-alcoholic Fatty Liver Disease and Fatty Liver. Intercept Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 595 general payments to Dr. McLaughlin from 38 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $2,503.

Dmand AI lists 1 award for Dr. McLaughlin, most recently CMS Stage 1 2012 in 2012.

Dr. McLaughlin is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.